Combination Therapy With Doxazosin and Tenoxicam for the Management of Lower Urinary Tract Symptoms

Urology

Volumn 74, Issue 2, 2009, Pages 431-435

  Ozdemir, Ismail ^a   Bozkurt, Ozan ^a   Demir, Omer ^a   Aslan, Guven ^a   Esen, Adil A ^a  

^a DOKUZ EYLUL UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

DOXAZOSIN; TENOXICAM;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DRUG EFFICACY; DRUG SAFETY; GASTROINTESTINAL DISEASE; HUMAN; INTERNATIONAL PROSTATE SYMPTOM SCORE; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; MALE; NOSE CONGESTION; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PRURITUS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT DURATION; URINE FLOW RATE; URINE RETENTION;

ADRENERGIC ALPHA-ANTAGONISTS; CYCLOOXYGENASE 2 INHIBITORS; DOXAZOSIN; DRUG THERAPY, COMBINATION; HUMANS; MALE; MIDDLE AGED; PIROXICAM; PROSTATIC HYPERPLASIA; URINATION DISORDERS; URODYNAMICS;

EID: 67651102648     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2009.01.088     Document Type: Article

References (24)

1. Garraway W.M., Collins G.N., and Lee R.J. High prevalence of benign prostatic hypertrophy in the community. Lancet 338 (1991) 469-471
2. Madersbacher S., Alivizatos G., Nordling J., et al. EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines). Eur Urol 46 (2004) 547-554
3. Savage S.J., Spungen A.M., Galea G., et al. Combination medical therapy for symptomatic benign prostatic hyperplasia. Can J Urol 5 (1998) 578-584
4. Di Silverio F., Bosman C., Salvatori M., et al. Combination therapy with rofecoxib and finasteride in the treatment of men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH). Eur Urol 47 (2005) 72-79
5. O'Neill G.P., and Ford-Hutchinson A.W. Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues. FEBS Lett 330 (1993) 156-160
6. Kirschenbaum A., Klausner A.P., Lee R., et al. Expression of cyclooxygenase-1 and cyclooxygenase-2 in the human prostate. Urology 56 (2000) 671-676
7. Hussain T., Gupta S., and Mukhtar H. Cyclooxygenase-2 and prostate carcinogenesis. Cancer Lett 191 (2003) 125-135
8. Masick J.M., Levin R.M., and Hass M.A. The effect of partial outlet obstruction on prostaglandin generation in the rabbit urinary bladder. Prostaglandins Other Lipid Mediat 66 (2001) 211-219
9. Park J.M., Yang T., Arend L.J., et al. Cyclooxygenase-2 is expressed in bladder during fetal development and stimulated by outlet obstruction. Am J Physiol 273 (1997) F538-F544
10. Maggi C.A. Prostanoids as local modulators of reflex micturition. Pharmacol Rev 25 (1992) 13-20
11. Nickel J.C., Pontari M., Moon T., et al. A randomized, placebo controlled, multicenter study to evaluate the safety and efficacy of rofecoxib in the treatment of chronic nonbacterial prostatitis. J Urol 169 (2003) 1401-1405
12. McConnell J.D., Roehrborn C.G., Bautista O.M., et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349 (2003) 2387-2398
13. Athanasopoulos A., Gyftopoulos K., Giannitsas K., et al. Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study. J Urol 169 (2003) 2253-2256
14. Lee J.Y., Kim H.W., Lee S.J., et al. Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder. BJU Int 94 (2004) 817-820
15. Lee K.S., Choo M.S., Kim D.Y., et al. Combination treatment with propiverine hydrochloride plus doxazosin controlled release gastrointestinal therapeutic system formulation for overactive bladder and coexisting benign prostatic obstruction: a prospective, randomized, controlled multicenter study. J Urol 174 (2005) 1334-1338
16. Kaplan S.A., Walmsley K., and Te A.E. Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia. J Urol 174 (2005) 2273-2275
17. Abrams P., Kaplan S., De Koning Gans H.J., et al. Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. J Urol 175 (2006) 999-1004
18. Nickel J.C., Downey J., Young I., et al. Asymptomatic inflammation and/or infection in benign prostatic hyperplasia. BJU Int 84 (1999) 976-981
19. Andersson K.E. LUTS treatment: future treatment options. Neurourol Urodyn 26 (2007) 934-947
20. Wang W., Bergh A., and Damber J.E. Chronic inflammation in benign prostate hyperplasia is associated with focal upregulation of cyclooxygenase-2, Bcl-2 and cell proliferation in the glandular epithelium. Prostate 61 (2004) 60-72
21. Angelico P., Guarneri L., Velasco C., et al. Effect of cyclooxygenase inhibitors on the micturition reflex in rats: correlation with inhibition of cyclooxygenase isoenzymes. BJU Int 97 (2006) 837-846
22. Park J.M., Yang T., Arend L.J., et al. Obstruction stimulates COX-2 expression in bladder smooth muscle cells via increased mechanical stretch. Am J Physiol 276 (1999) F129-F136
23. Kirby R.S., Andersen M., and Gratzke P. A combined analysis of double-blind trials of the efficacy and tolerability of doxazosin-gastrointestinal therapeutic system, doxazosin standard and placebo in patients with benign prostatic hyperplasia. BJU Int 87 (2001) 192-200
24. Richy F., Bruyere O., Ethgen O., et al. Time dependent risk of gastrointestinal complications induced by non-steroidal anti-inflammatory drug use: a consensus statement using a meta-analytic approach. Ann Rheum Dis 63 (2004) 759-766